Brief: Immutep’s Sarcoma Trial Data Accepted for Oral Presentation at CTOS 2025
08/09/2025 13:16
Sept 8 (Reuters) - Immutep Ltd IMM.AX: IMMUTEP ANNOUNCES DATA FROM EFTISARC-NEO PHASE II EVALUATING NEOADJUVANT EFTI IN SOFT TISSUE SARCOMA ACCEPTED FOR ORAL PRESENTATION AT CTOS 2025 Source text: ID:nGNXb5sTsw Further company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))